F. Lavie

发表

Transition to ustekinumab in patients with moderate‐to‐severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)

S. Chimenti, J. Lambert, T. Luger, 2014, The British journal of dermatology.

Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: development of recommendations for clinical practice based on published evidence and expert opinion.

A. Saraux, P. Goupille, B. Combe, 2009, Joint, bone, spine : revue du rhumatisme.

Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.

A. Saraux, P. Goupille, B. Combe, 2009, Joint, bone, spine : revue du rhumatisme.

Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.

X. Mariette, A. Saraux, P. Goupille, 2007, Joint, bone, spine : revue du rhumatisme.

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

M. Dougados, J. Sieper, A. Pangan, 2011, Annals of the rheumatic diseases.

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

S. Vermeire, G. D'Haens, D. Gaya, 2022, The lancet. Gastroenterology & hepatology.

Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé

D. Gladman, A. Deodhar, P. Mease, 2022, Annals of the rheumatic diseases.

Bronchiectasis in a patient with CREST syndrome.

B. Fautrel, S. Rozenberg, P. Bourgeois, 2002, Joint, bone, spine : revue du rhumatisme.

CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome.

X. Mariette, J. Gottenberg, J. Delfraissy, 2005, Journal of autoimmunity.

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

X. Mariette, J. Gottenberg, J. Sellam, 2006, Annals of the rheumatic diseases.

105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

S. Vermeire, G. D'Haens, D. Gaya, 2021 .

Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?

X. Mariette, J. Gottenberg, J. Sellam, 2008, Rheumatology.

Failure to confirm coxsackievirus infection in primary Sjögren's syndrome.

X. Mariette, P. Nordmann, J. Gottenberg, 2006, Arthritis and rheumatism.

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome

H. Zouali, X. Mariette, J. Gottenberg, 2006, Arthritis research & therapy.

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study

M. Dougados, D. Heijde, A. Deodhar, 2013, Annals of the rheumatic diseases.

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

E. Theander, P. Sfikakis, S. Siebert, 2022, Annals of the rheumatic diseases.

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

E. Theander, P. Sfikakis, S. Siebert, 2022, Annals of the Rheumatic Diseases.

[Bilateral intracranial subdural hematoma following lumbar puncture: report of a case].

D. Hervé, I. Le Ber, S. Sangla, 1998, Revue neurologique.

Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome

X. Mariette, J. Quillard, P. Leclerc, 2004, The Journal of pathology.

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome

X. Mariette, R. Kimberly, S. Roux, 2003, Annals of the rheumatic diseases.

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

X. Mariette, J. Sellam, T. Lazure, 2006, Arthritis research & therapy.

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus

X. Mariette, J. Gottenberg, O. Lambotte, 2006, Annals of the rheumatic diseases.

Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.

X. Mariette, A. Saraux, P. Goupille, 2007, Joint, bone, spine : revue du rhumatisme.

Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls

M. Dougados, A. Feydy, L. Gossec, 2011, Annals of the Rheumatic Diseases.

Focal myositis with fasciitis and vasculitis revealing chronic lymphocytic leukaemia.

X. Mariette, B. Terrier, F. Lavie, 2005, Rheumatology.

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis

A. Gottlieb, P. Rahman, P. Mease, 2023, RMD Open.

B‐cell Activating Factor of the Tumour Necrosis Factor Family Expression in Blood Monocytes and T Cells from Patients with Primary Sjögren’s Syndrome

X. Mariette, J. Gottenberg, J. Sellam, 2008, Scandinavian journal of immunology.

Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

G. Girolomoni, F. Sampogna, P. Bergmans, 2017, The British journal of dermatology.

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome

X. Mariette, J. Gottenberg, R. Kimberly, 2005, Annals of the rheumatic diseases.

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

X. Mariette, N. Casadevall, V. Soumelis, 2007, Haematologica.

The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis

M. Dougados, P. Conaghan, J. Smolen, 2007, Annals of the rheumatic diseases.

Retroperitoneal fibrosis secondary to spondylodiscitis after infection with Prevotella.

X. Mariette, C. Salliot, A. Miquel, 2005, The Journal of rheumatology.

Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO

G. Girolomoni, F. Sampogna, P. Bergmans, 2018, The British journal of dermatology.

Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion.

A. Saraux, P. Goupille, B. Combe, 2009, Joint, bone, spine : revue du rhumatisme.

Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.

X. Mariette, A. Saraux, P. Goupille, 2007, Joint, bone, spine : revue du rhumatisme.

Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy

L. Coates, D. Gladman, C. May, 2010 .

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

E. Theander, P. Sfikakis, S. Siebert, 2023, Arthritis Research & Therapy.

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study

E. Theander, S. Siebert, L. Gossec, 2023, Arthritis Research & Therapy.

Physicians in the pharmaceutical industry: their roles, motivations, and perspectives.

H. Sweiti, F. Lavie, M. Schuier, 2019, Drug discovery today.

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

L. Coates, S. Siebert, S. Chakravarty, 2023, Arthritis Research & Therapy.

Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.

A. Ogdie, P. Mease, S. Chakravarty, 2023, Clinical rheumatology.

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data

E. Theander, S. Siebert, L. Gossec, 2023, Rheumatology.

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

L. Coates, S. Siebert, S. Chakravarty, 2023, Arthritis Research & Therapy.

Clinical and epidemiological research

M. Dougados, D. Heijde, J. Sieper, 2011 .

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome

H. Zouali, X. Mariette, J. Gottenberg, 2006, Arthritis research & therapy.